Related Experiment Video
Updated: Nov 5, 2025
Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
Published on: November 4, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review
Ather Adnan1, Priscilla R Powell, Cecil Jordan Staples
1Medical Student, College of Medicine, Texas A&M Health Science Center, Houston, TX; Resident Physician, Department of Pathology, Baylor Scott and White Medical Center, Temple, TX; Intern, Department of Internal Medicine, University of Texas Austin Dell Medical School, Austin, TX; Clinical Assistant Professor, Department of Dermatology, Baylor Scott and White Medical Center, Temple, TX; and Clinical Associate Professor, Department of Dermatology and Pathology, Baylor Scott and White Medical Center, Temple, TX.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive cancer with skin symptoms. Recognizing its varied appearance and unique markers is key to avoiding misdiagnosis and ensuring timely treatment.
Area of Science:
- Hematology
- Dermatology
- Oncology
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy.
- It often presents with cutaneous manifestations, posing diagnostic challenges.
- BPDCN shares immunohistochemical markers with acute myeloid leukemia, increasing misdiagnosis risk.
Purpose of the Study:
- To highlight the diagnostic challenges of BPDCN.
- To review the cutaneous and histopathologic characteristics of BPDCN.
- To increase awareness of this rare entity.
Main Methods:
- Case series presentation.
- Review of cutaneous manifestations.
- Analysis of histopathologic and immunophenotypic features.
Main Results:
- BPDCN presents heterogeneously, from solitary nodules to disseminated lesions.
- Tumor cells express markers common to acute myeloid leukemia.
- Awareness of unique histopathology and immunophenotype is crucial.
Conclusions:
- Timely diagnosis of BPDCN requires recognizing its diverse skin presentations.
- Understanding BPDCN's unique features aids in differentiating it from other malignancies.
- Early diagnosis improves patient outcomes for this aggressive neoplasm.
